Total Payments
$40,275
2024 Payments
$10,704
Companies
4
Transactions
37
Medicare Patients
1,305
Medicare Billing
$153,583
Payment Breakdown by Category
Consulting$24,213 (60.1%)
Research$14,093 (35.0%)
Travel$1,514 (3.8%)
Food & Beverage$455.71 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $24,213 | 10 | 60.1% |
| Unspecified | $14,093 | 14 | 35.0% |
| Travel and Lodging | $1,514 | 6 | 3.8% |
| Food and Beverage | $455.71 | 7 | 1.1% |
Payments by Type
General
$26,182
23 transactions
Research
$14,093
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $28,942 | 21 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,639 | 12 | $0 (2024) |
| Mitsubishi Tanabe Pharma America, Inc. | $3,681 | 3 | $0 (2017) |
| PFIZER INC. | $11.97 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,704 | 13 | Regeneron Pharmaceuticals, Inc. ($7,639) |
| 2023 | $4,598 | 3 | Biogen, Inc. ($4,598) |
| 2022 | $2,004 | 2 | Biogen, Inc. ($1,992) |
| 2021 | $7,088 | 1 | Biogen, Inc. ($7,088) |
| 2020 | $8,193 | 2 | Biogen, Inc. ($8,193) |
| 2019 | $2,041 | 2 | Biogen, Inc. ($2,041) |
| 2018 | $1,966 | 11 | Biogen, Inc. ($1,966) |
| 2017 | $3,681 | 3 | Mitsubishi Tanabe Pharma America, Inc. ($3,681) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,205.00 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,564.00 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $961.50 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $31.66 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $112.79 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $64.41 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $154.82 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $317.10 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $35.25 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2024 | Biogen, Inc. | QALSODY (Drug) | — | Cash or cash equivalent | $3,065.00 | Research |
| Study: A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension • Category: Neurology | ||||||
| 09/05/2023 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,452.00 | General |
| 05/25/2023 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $919.50 | General |
| 01/03/2023 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,226.00 | General |
| 11/16/2022 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG, PAXLOVID | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 02/04/2022 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,992.26 | General |
| 04/13/2021 | Biogen, Inc. | — | — | Cash or cash equivalent | $7,087.50 | Research |
| Study: A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension | ||||||
| 12/15/2020 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,260.00 | General |
| 12/01/2020 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,932.50 | General |
| 10/13/2019 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | Cash or cash equivalent | $67.19 | General |
| Category: NEUROLOGY | ||||||
| 05/30/2019 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,974.03 | Research |
| Study: An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $64.98 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $53.94 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension | Biogen, Inc. | $10,153 | 2 |
| An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | Biogen, Inc. | $1,974 | 1 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Biogen, Inc. | $1,966 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 462 | 603 | $238,928 | $52,235 |
| 2022 | 10 | 243 | 305 | $115,675 | $28,308 |
| 2021 | 11 | 268 | 348 | $131,205 | $34,035 |
| 2020 | 14 | 332 | 448 | $145,644 | $39,004 |
Total Patients
1,305
Total Services
1,704
Medicare Billing
$153,583
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 74 | $24,050 | $7,101 | 29.5% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 97 | 132 | $28,908 | $6,441 | 22.3% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 30 | 31 | $27,311 | $5,190 | 19.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 55 | 61 | $21,106 | $4,623 | 21.9% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 21 | 21 | $25,137 | $4,491 | 17.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 67 | $14,874 | $3,940 | 26.5% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 20 | 20 | $20,640 | $3,918 | 19.0% |
| 95937 | Testing of nerve-muscle junction | Office | 2023 | 11 | 48 | $14,064 | $3,897 | 27.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 26 | 26 | $18,928 | $3,357 | 17.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 33 | $13,695 | $3,271 | 23.9% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 25 | 25 | $13,825 | $2,649 | 19.2% |
| 95908 | Nerve conduction, 3-4 studies | Office | 2023 | 16 | 16 | $7,376 | $1,315 | 17.8% |
| 95887 | Needle measurement of electrical activity in trunk or head muscles | Office | 2023 | 16 | 16 | $4,944 | $1,058 | 21.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $2,508 | $704.11 | 28.1% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 13 | 22 | $1,562 | $281.91 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 67 | $21,775 | $6,406 | 29.4% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 59 | 88 | $18,216 | $4,463 | 24.5% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2022 | 15 | 15 | $16,920 | $3,537 | 20.9% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 15 | 15 | $12,465 | $2,398 | 19.2% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 17 | 17 | $11,662 | $2,354 | 20.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 26 | 28 | $9,128 | $2,277 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 15 | $6,525 | $2,154 | 33.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 36 | $7,884 | $2,053 | 26.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $7,500 | $1,825 | 24.3% |
| 95887 | Needle measurement of electrical activity in trunk or head muscles | Office | 2022 | 11 | 12 | $3,600 | $841.49 | 23.4% |
About Dr. Robert Bucelli, MD
Dr. Robert Bucelli, MD is a Neurology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1295932960.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Bucelli, MD has received a total of $40,275 in payments from pharmaceutical and medical device companies, with $10,704 received in 2024. These payments were reported across 37 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($24,213).
As a Medicare-enrolled provider, Bucelli has provided services to 1,305 Medicare beneficiaries, totaling 1,704 services with total Medicare billing of $153,583. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Saint Louis, MO
- Active Since 06/27/2007
- Last Updated 04/15/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1295932960
Products in Payments
- LIBTAYO (Biological) $7,639
- Radicava (Drug) $3,681
- QALSODY (Drug) $3,065
- SPINRAZA (Biological) $67.19
- PANZYGA (Biological) $11.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Saint Louis
Barry Singer
Neurology — Payments: $2.7M
Neurology $2.7M
Dr. Mark Tullman, M.d, M.D
Neurology — Payments: $2.1M
Neurology $2.1M
Dr. Robert Naismith, Md, MD
Neurology — Payments: $774,163
Neurology $774,163
Dr. Barbara Green, Md, MD
Neurology — Payments: $597,464
Neurology $597,464
Dr. Arun Varadhachary, Md, MD
Neurology — Payments: $373,665
Neurology $373,665
Dr. Anne Cross, Md, MD
Neurology — Payments: $270,789
Neurology $270,789